|
|
|
|
Дата |
|---|
| 11.03.2026 |
| 10.03.2026 |
| 09.03.2026 |
| 06.03.2026 |
| 05.03.2026 |
| 04.03.2026 |
| 03.03.2026 |
| 27.02.2026 |
| 26.02.2026 |
| 25.02.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
|
|
|
|
|
|
1 651.00
|
|
|
|
|
Olipass Corporation operates nucleic acid biotechnology businesses. The Company mainly develops and produces artificial nuclease therapeutic agents. Olipass also researches gene and protein biotechnologies.
